Ascendis Pharma is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained-release technologies, to develop a pipeline of best‐in‐class therapeutics that address significant unmet medical needs. The TransCon technology can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. In addition to our current pipeline of three rare disease endocrinology candidates, we have established oncology as our second therapeutic area of focus.
The Ascendis Pharma pipeline includes TransCon Growth Hormone, for which we have completed enrollment in the Phase 3 heiGHt Trial for once-weekly in children with pediatric GHD. Top-line results from this trial are expected in the first quarter of 2019. Ascendis Pharma is also developing two additional rare disease product candidates, TransCon PTH and TransCon CNP. In addition to its internal programs, Ascendis Pharma has formed collaborations focused on leading products in large markets that are of strategic importance to its partners. These collaborations are with Sanofi in the field of diabetes and Roche Genentech in the field of ophthalmology.
Ascendis Pharma is headquartered in Copenhagen, Denmark, maintains an office in Palo Alto, California and has research and development facilities in Heidelberg, Germany and Copenhagen, Denmark.
TransCon Technology Platform
Learn how we’re using our innovative TransCon technology (short from “transient conjugation”) to create best-in-class products to address unmet patient needs. Watch Video